Clinical Trial Update: A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

The document reports an ongoing Phase 2 clinical trial evaluating LBL-007 in combination with tislelizumab and chemotherapy for unresectable locally advanced or…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• LBL-007
• Tislelizumab (tislelizumab)

Snippet

Sponsor: BeiGene | Conditions: Esophageal Cancer, Esophageal Squamous Cell Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING